TOLERABILITY AND EFFICACY OF DAPAGLIFLOZIN IN NON – DIABETIC HEART FAILURE PATIENTS
DOI:
https://doi.org/10.71000/r97cc466Keywords:
Dapagliflozin, heart failure, HFrEF, non-diabetic, NYHA classification, , Pro-BNP, , SGLT2 inhibitorsAbstract
Background: Heart failure (HF) remains a major global health burden with limited treatment options, especially in non-diabetic populations. Sodium–glucose co-transporter 2 inhibitors (SGLT2is), such as dapagliflozin, have shown promising cardiovascular benefits beyond glycemic control. While most studies have focused on diabetic patients, emerging evidence suggests potential efficacy in non-diabetic HF cohorts. Understanding dapagliflozin's role in improving clinical outcomes in this specific population is essential for refining heart failure treatment strategies.
Objective: To evaluate the clinical efficacy and tolerability of dapagliflozin in non-diabetic patients with heart failure.
Methods: This descriptive study was conducted over five months at the Department of Cardiology, PIMS, Islamabad. A total of 150 non-diabetic HF patients, aged 30–70 years, were enrolled using non-probability consecutive sampling. Participants received oral dapagliflozin 10 mg daily for 12 weeks. Baseline and post-treatment assessments included Pro-BNP levels and NYHA functional class. Tolerability was monitored through adverse event reporting. Statistical analysis was performed using IBM SPSS version 23. Quantitative variables were expressed as means ± SD, and categorical variables as frequencies and percentages. A p-value of ≤ 0.05 was considered statistically significant.
Results: After 12 weeks, 66 participants (44.0%) achieved Pro-BNP normalization (<450 pg/mL), and 72 (48.0%) improved to NYHA Class I (p < 0.001 for both). A combined efficacy outcome was observed in 58 patients (38.7%). The drug was well-tolerated by 124 individuals (82.7%) without major adverse events. Subgroup analysis revealed higher efficacy in HFrEF patients (50.0%) compared to HFpEF (36.5%) (p = 0.03).
Conclusion: Dapagliflozin significantly improves functional and biomarker outcomes in non-diabetic HF patients, especially those with reduced ejection fraction. Its favorable safety profile supports broader clinical application, though long-term evaluation is warranted.
References
Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E, Katova T, Ljungman CE, Diez M, Ogunniyi MO, Langkilde AM. Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA cardiology. 2021 Jun 1;6(6):678-89.
Anitha AP, Balasubramanian S, Ramalingam AG, Samuel Kennady SR, Ganamurali N, Dhanasekaran D, Sabarathinam S. An exploration of the experience of dapagliflozin in clinical practice. Future Science OA. 2022 Sep 1;8(8): FSO816.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology. 2021 Jan 26;77(3):243-55.
Rosano G, Quek D, Martínez F. Sodium–glucose co-transporter 2 inhibitors in heart failure: recent data and implications for practice. Cardiac failure review. 2020 Nov 13;6: e31..
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. Jama. 2020 Apr 14;323(14):1353-68.
Ma F, Zhang J, Wang H, Wu Y, Wu Y. [Retracted] Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function. Disease Markers. 2022;2022(1):4829750.
Zargar AH, Trailokya AA, Ghag S, Pawar R, Aiwale A, Zalke A. Current role of dapagliflozin in clinical practice. The Journal of the Association of Physicians of India. 2021 Sep;69(9):11-2.
Maltês S, Cunha GJ, Rocha BM, Presume J, Guerreiro R, Henriques C, Rodrigues C, Araújo I, Fonseca C. Dapagliflozin in a real-world chronic heart failure population: how many are actually eligible. Cardiology. 2021 Mar 19;146(2):201-6.
Håkansson E, Norberg H, Själander S, Lindmark K. Eligibility of Dapagliflozin and Empagliflozin in a Real‐World Heart Failure Population. Cardiovascular Therapeutics. 2021;2021(1):1894155.
Rasmussen DGK, Hansen MK, Frederiksen P, Luo Y, Pehrsson M, Neal B, et al. Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis. Diabetes Obes Metab. 2024;26(9):4060-8.
Tanaka A, Node K. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care. Cardiovasc Diabetol. 2020;19(1):132.
Genuardi MV, Mather PJ. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Ther Adv Cardiovasc Dis. 2021;15:17539447211002678.
Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, et al. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. Cardiovasc Diabetol. 2021;20(1):175.
Gamaza-Chulián S, Díaz-Retamino E, González-Testón F, Gaitero JC, Castillo MJ, Alfaro R, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study. BMC Cardiovasc Disord. 2021;21(1):456.
Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20(1):25.
Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, Sehner S, Zeller T, Gerhardt LMS, et al. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure. Nat Cardiovasc Res. 2023;2(11):1032-43.
Yan Q, Chen X, Yu C, Yin Y. Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24(1):663.
Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021;23(6):1026-36.
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29.
Kasperova BJ, Mraz M, Svoboda P, Hlavacek D, Kratochvilova H, Modos I, et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc Diabetol. 2024;23(1):223.
Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):17.
Alshehri A, Guan D, Li P, Zhang Y, Ghayee HK, Jiao T, et al. Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019. Prim Care Diabetes. 2024;18(5):561-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Shah Jihan, Mahboob Ur Rehman, Yasir Ashraf, Muhammad Asif Nawaz khan, Nouman Khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
